JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (3): 72-76.doi: 10.6040/j.issn.1671-7554.0.2015.315

Previous Articles     Next Articles

Effects of rosiglitazone and GW9662 on the expression of PPAR-γ in JEG-3 cells

LI Zhishuang1, YU Qiong1, ZHANG Chunhua2   

  1. 1. Department of Pathology, Medical School of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Gynecology and Obstetrics, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2015-03-23 Online:2016-03-10 Published:2016-03-10

PDF (PC)

332

Abstract: Objective To investigate the effects of peroxisome proliferator-activated receptor gamma(PPAR-γ)agonist rosiglitazone and antagonist GW9662 on PPAR-γ expression and invasion ability of JEG-3 cells. Methods Immunohistochemistry method was used to detect PPAR-γ expression and distribution in normal chorionic, hydatidiform mole and choriocarcinoma tissues. Then PPAR-γ expression in rosiglitazone, GW9662 and control groups were examined respectively by Transwell assay, immunocytochemistry, Western blotting and qPCR method. Results PPAR-γ was expressed and distributed in cell nucleus of normal chorionic, hydatidiform mole and choriocarcinoma tissues, and its expression was significant down-regulated in choriocarcinoma tissues. Invasion ability of JEG-3 cells treated by rosiglitazone was decreased, while that of GW9662 group was increased. There was a statistical significance between the two groups(P<0.05). The expression of PPAR-γ in rosiglitazone group was lower than that in GW9662 group(P<0.05). Conclusion The activity of PPAR-γ is modulated via a negative feedback regulation mechanism by rosiglitazone and GW9662, and can influence the invasion ability of choriocarcinoma cells.

Key words: Peroxisome proliferator-activated receptor gamma, Choriocarcinoma, Rosiglitazone, GW9662

CLC Number: 

  • R737.33
[1] Khoo SK. Clinical aspects of gestational trophoblastic disease:a review based partly on 25-year experience of a statewide registry[J]. Aust N Z J Obstet Gynaecol, 2003, 43(4):280-289.
[2] Parast MM, Yu H, Ciric A, et al. PPARgamma regulates trophoblast proliferation and promotes labyrinthine trilineage differentiation[J]. PLoS One, 2009, 4(11):e8055. doi:10.1371/journal.pone.0008055.
[3] Marvin KW, Eykholt RL, Keelan JA, et al. The 15-deoxy-delta(12, 14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma(PPARgamma)is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells[J]. Placenta, 2000, 21(4):436-440.
[4] Narala VR, Subramani PA, Narasimha VR, et al. The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation[J]. Int Immunopharmacol, 2014, 23(1):283-287.
[5] Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer[J]. Cancer Res, 2000, 60(4):1129-1138.
[6] Medina A, Ramos M, Amenedo M, et al. Choriocarcinoma syndrome[J]. Arch Esp Urol, 2014, 67(8):711-714.
[7] Suwaki N, Masuyama H, Masumoto A, et al. Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy[J]. Placenta, 2007, 28(4):315-323.
[8] Sanz MJ, Albertos F, Otero E, et al. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-gamma activation[J]. J Immunol, 2012, 189(1):411-424.
[9] 刘华, 陈昊, 唐照, 等. 全反式维甲酸通过DOK1/PPARγ信号通路抑制人乳腺癌细胞MCF-7的增殖[J]. 中国病理生理杂志, 2015, 31(7):1178-1183. LIU Hua, CHEN Hao, TANG Zhao, et al. All-trans retinoic acid supprewsses proliferation of breast cancer cells through DOK1/PPARγ pathway[J]. Chinese Journal of Pathophysiology, 2015, 31(7):1178-1183.
[10] Capparuccia L, Marzioni D, Giordano A, et al. PPARgamma expression in normal human placenta, hydatidiform mole and choriocarcinoma[J]. Mol Hum Reprod, 2002, 8(6):574-579.
[11] Ninomiya I, Yamazaki K, Oyama K, et al. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells[J]. Oncol Lett, 2014, 8(6):2709-2714.
[12] Choudhary R, Li H, Winn RA, et al. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail[J]. Neoplasia, 2010, 12(3):224-234.
[13] Yoshizumi T, Ohta T, Ninomiya I, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects[J]. Int J Oncol, 2004, 25(3):631-639.
[14] Apostoli AJ, Roche JM, Schneider MM, et al. Opposing roles for mammary epithelial-specific PPARgamma signaling and activation during breast tumour progression[J]. Mol Cancer, 2015, 14:85. doi:10.1186/s12943-015-0347-8.
[15] Wang Y, Tan H, Xu D, et al. The combinatory effects of PPAR-gamma agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells[J]. Int J Mol Med, 2014, 34(1):262-268.
[16] Levytska K, Drewlo S, Baczyk D, et al. PPAR- gamma Regulates Trophoblast Differentiation in the BeWo Cell Model[J]. PPAR Res, 2014, 2014:637251.
[1] LU Xiang-Dong, YANG Wei, XU Guang-Meng, QU Yuan-Ming. Expression and role of PPAR-γin meningiomas and troglitazone induced meningiomas cell apoptosis in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 65-.
[2] CHU Qian-qian1, XU Gang2, REN Gui-jie1, XU Xia1, HU Zhong-yi1, LIU Yong-qing1, YUAN Hui-qing1, TIAN Ke-li1. Effect of rosiglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, in sensitizing 5-fluorouracil chemotherapy for colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 66-71.
[3] CHE Xiao-qi, LI Yin-yin, WANG Zhe, CHEN Hai-yan, ZHOU Jie. Effects of improved insulin resistance on the level of serum  glucagon-like peptide-1 in type 2 diabetic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(6): 5-7.
[4] ZU Zengyan1, ZHANG Guiyu1, MA Benhong1, WANG Hongxia2 . Inhibitory effect of rosiglitazone combined with cisplatin on the growth of endometrial carcinoma in Nude Mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(5): 62-66.
[5] LU Xiang-Dong, YANG Wei, XU Guang-Meng, QU Yuan-Ming. Expression and role of PPAR-γin meningiomas and troglitazone induced meningiomas cell apoptosis in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(6): 65-.
[6] . Effects of the Rosiglitazone on expressions of MMP2 and TIMP1 mRNA in hepatic stellate cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(11): 74-75.
[7]

SUN Ying1，2， LIU Yi3，　ZHANG Jie2，　CUI Bin2，　KONG Lei1，　ZHAO Jiajun1

.

Effects of Rosiglitazone on activities of AMPK
in the skeletal muscle of highfat fed rats

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(03): 48-52.
[8] LI Yan1,2, WANG Yi1, HUANG Lei2, AN Xiangmei2, ZHOU Yaping2
.

Effect of different interventional modalities on expression of resistin in dietinduced hyperresistinemia in rats

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(03): 39-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd